Lipid pathway deregulation in advanced prostate cancer

Pharmacol Res. 2018 May:131:177-184. doi: 10.1016/j.phrs.2018.02.022. Epub 2018 Feb 18.

Abstract

The link between prostate cancer (PC) development and lipid metabolism is well established, with AR intimately involved in a number of lipogenic processes involving SREBP1, PPARG, FASN, ACC, ACLY and SCD1. Recently, there is growing evidence implicating the role of obesity and peri-prostatic adipose tissue (PPAT) in PC aggressiveness and related mortality, suggesting the importance of lipid pathways in both localised and disseminated disease. A number of promising agents are in development to target the lipogenic axis in PC, and the likelihood is that these agents will form part of combination drug strategies, with targeting of multiple metabolic pathways (e.g. FASN and CPT1), or in combination with AR pathway inhibitors (SCD1 and AR).

Keywords: Lipid; Metabolism; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Discovery
  • Fatty Acid Synthases / metabolism
  • Humans
  • Lipid Metabolism* / drug effects
  • Male
  • PPAR gamma / metabolism
  • Prostate / drug effects
  • Prostate / metabolism*
  • Prostate / pathology
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Signal Transduction / drug effects
  • Sterol Regulatory Element Binding Protein 1 / metabolism

Substances

  • PPAR gamma
  • Sterol Regulatory Element Binding Protein 1
  • Fatty Acid Synthases